Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Phase II Trial on Induction Immunochemotherapy Followed by Surgery or Definitive Chemoradiation and Consolidation Durvalumab (MEDI4736) in Resectable and Borderline Resectable Stage IIIA/B NSCLC

NCT06810609 is registered in ClinicalTrials.gov with University Hospital, Bonn as lead sponsor.

NCT NCT06810609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06810609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Phase II Trial on Induction Immunochemotherapy Followed by Surgery or Definitive Chemoradiation and Consolidation Durvalumab (MEDI4736) in Resectable and Borderline Resectable Stage IIIA/B NSCLC
Lead sponsor
University Hospital, Bonn
Phase
Phase 2
Overall status
Recruiting
Start date
April 20, 2025
Completion date
September 30, 2030
Enrollment
176 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer non-small cell cancer (nsclc)